Nevertheless, Shoaib et al
The challenge occurs when a medicinal product (same strength and route of administration) is approved and used for two or more equally important indications, and the main therapeutic use differs from one country to another
GLP-1 receptor agonist medications (including semaglutide, dulaglutide, liraglutide, exenatide, and lixisenatide) are typically considered for type 2 diabetes when: Triple therapy with other diabetes medications is not effective, not tolerated, or contraindicated The person has a BMI 35 kg/m (adjusted by 2.5 kg/m for people from South Asian, Chinese, other Asian, Black African, or African-Caribbean backgrounds) and specific weight-related psychological or medical problems A lower BMI threshold may be appropriate if weight loss would benefit other obesity-related comorbidities Insulin would not be appropriate or acceptable to the person Treatment is usually continued only if there is a beneficial metabolic response (reduction in HbA1c and weight) after 6 months
Recombinant human IGF-1 is usually synthesised in E
Whether its because their names sound similar or because they both offer benefits, its easy to get them confused
Conjugation It binds to toxins, forming conjugates that are more easily eliminated from the body, aiding in detoxification
.png)
